The effects and efficacy of Ribociclib

In pre- and postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC), aromatase inhibitors (AI or fulvestrant) with CDK The combination of the 4/6 inhibitor ribociclib has demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with standard single-agent hormonal therapy as first-line treatment for new metastatic disease or recurrence during or after adjuvant therapy.

Based on a phase III study, the combination of ribociclib and letrozole was approved by the FDA. In this study, 668 postmenopausal women with HR+, HER2-negative recurrent or metastatic breast cancer received first-line letrozole with or without ribociclib. For patients with metastatic disease, results from the MONALEESA-3 trial showed that reboxiclib was effective in combination with fulvestrant, and the FDA approved this combination for initial and subsequent endocrine therapy in postmenopausal women with metastatic hormone receptor-positive, HER2-negative BC. In both adjuvant and neoadjuvant settings, the use of CDK 4/6 inhibitors may help improve outcomes in high-risk patients with HR+ BC, but data are in contrast to phase III studies that yielded positive results.

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.